TAK241220C22500
- 0.00
- 0.000.00%
Takeda Pharmaceutical Newsroom
TD Cowen Maintains Takeda Pharmaceutical(TAK.US) With Buy Rating
List of converted stocks (Part 2) [List of converted stocks for Parabolic Signal]
○List of stocks converting to Sell Market Code Stock Name Closing Price SAR Main Board <1720> Tokyu Construction 700 715 <1803> Shimizu Construction 1215 1248 <1878> Daito Construction 1767 518225 <1882> Toa Road 1280 1311 <1925> Daiwa House 4717 4849 <1928> Sekisui House 3579 3730 <1934> Euretec 1436 1472 <1952
Teva Pharmaceutical Releases Impressive Phase 2 Candidate Data For Gastro-Related Diseases
Takeda Pharmaceutical: Revised Extraordinary Report
ADR Japanese stock rankings - general Sell pressure including Yuucho Bank, Chicago down 145 yen compared to Osaka at 39,255 yen.
Japanese stocks of ADR (American Depositary Receipt) compared to the Tokyo Stock Exchange (calculated at 153.48 yen per dollar) include Yu-cho Bank <7182>, SoftBank Group <9984>, Nidec <6594>, Renesas <6723>, Sony Group Corp <6758>, Murata Manufacturing <6981>, DAIKIN INDUSTRIES, LTD. Unsponsored ADR <6367>, all of which have declined, indicating a general trend towards Sell. The clearing price for Chicago Nikkei 225 Futures is down 145 yen from the Osaka daytime price, now at 39,255 yen. The U.S. stock market has fallen. The Dow Inc decreased by 267.58 dollars, now at 43,449.
Takeda Pharmaceutical (TAK.US) CD38 monoclonal antibody has been approved for clinical use again in China.
Takeda Pharmaceutical's CD38 monoclonal antibody has been approved for clinical use in China again.
Regarding the launch of the strategic partnership "Project Soten" between Takeda Pharmaceutical and Tohoku Universities to accelerate the research and development of Innovative Drugs.
On December 17, 2024, Takeda Pharmaceuticals Sp Adr and Tohoku University announced the launch of a strategic alliance "Project Sōten" to accelerate research and development of Innovative Drugs - Building an advanced clinical trial acceleration model aimed at improving medical access for regional patients and strengthening domestic drug development capabilities - Accelerating the establishment of a medical network and healthcare data infrastructure centered on Tohoku University Hospital, promoting research and development of new drugs and treatments through integrated analysis, and contributing to the world from Tohoku.
Takeda Pharmaceutical Unveils $10 Billion-$20 Billion Late-Stage Pipeline
6-K: Takeda Spotlights High-Value, Late-Stage Pipeline Accelerating the Development of Potential Transformative Treatments for Patients in Multiple Therapeutic Areas
HUTCHMED (China) to Receive $10 Million Milestone Payment From Takeda After First European Reimbursement for Fruzaqla
Express News | Takeda Plans To Host An Investor R&D Day; Expects Six Late-Stage Programs With Peak Revenue Potential Of $10B - $20B To Deliver Sustainable Growth
List of Switching Stocks (Part 1) [Parabolic Signal Switching Stocks List]
○ List of stocks for Buy conversion in the market Code Stock Name Closing Price SAR Main Board <1605> INPEX 1982 1944 <1662> Petroleum Resources 1096 1056 <1938> Nihon Reitech 1127 1082 <1939> Shikoku Electric Power 1468 1427 <2127> Japan M&A 6496 616 <2150> CareNet 5915 71 <2335> CubeSys 1066 1037 <26
ADR Japan stock ranking~ General buying dominance such as Toyota Industries, Chicago at 39,335 yen, 305 yen higher than Osaka~
Japanese stocks of American Depositary Receipts (ADRs), when compared to the Tokyo Stock Exchange (converted at 1 dollar to 150.01 yen), saw increases for Toyota Industries <6201>, KDDI Corporation <9433>, Mitsubishi Corporation <8058>, Honda Motor Co., Ltd. <7267>, Tokyo Electron <8035>, Tokio Marine Holdings <8766>, Mizuho Financial Group <8411>, etc., with overall buying preference. The settlement price of Chicago Nikkei 225 futures was 305 yen higher than the Osaka intraday price, at 39,335 yen. The U.S. stock market is mixed. The Dow Jones Industrial Average is down 123.19 dollars at 44,6.
Takeda Pharmaceutical: To Receive Y55B From Sale of 49% Stake in JV With Teva Pharmaceutical Industries
Regarding the transfer of the shareholding in Takeda Teva Pharma Co., Ltd.
Regarding the transfer of the shares held by the company of Takeda Teva Pharma Co., Ltd. On December 5, 2024, the company will transfer all of its 49% shareholding in the issued shares of Takeda Teva Pharma Co., Ltd. (hereinafter referred to as "Takeda Teva Pharma") to Teva Pharmaceutical Industries Limited (hereinafter referred to as "Teva") which will manage all the issued shares of Takeda Teva Pharma through a fund operated by J Will Partners Inc.
Takeda Pharmaceutical (TAK.US) collaborates with keros therapeutics to develop innovative treatments for blood diseases.
Takeda Pharmaceutical (TAK.US) is collaborating with keros therapeutics to develop innovative therapies for blood diseases.
The Nikkei average started up 105 yen, with DeNA and Itochu among those rising.
[Nikkei Average Stock Price・TOPIX (Table)] Nikkei Average; 39354.00; +105.14 TOPIX; 2755.80; +2.22 [Opening Overview] On the 4th, the Nikkei Average started trading at 39354.00 yen, up 105.14 yen, marking the third consecutive rise. The U.S. stock market on the previous day, the 3rd, showed mixed results. Dow Inc. closed down 76.47 dollars at 44705.53 dollars, while the Nasdaq finished up 76.96 points at 19480.91. The announcement of this week's employment statistics is approaching.
ADR Japanese stock rankings - mixed highs and lows, Chicago is up 90 yen compared to Osaka at 39,240 yen.
Japanese stocks of ADR (American Depositary Receipt) rose compared to the Tokyo Stock Exchange (calculated at 1 dollar to 149.66 yen), with Denso <6902>, Hoya <7741>, Tokio Marine HD <8766>, Fast Retailing <9983>, Disco <6146>, etc. On the other hand, Japan Post <6178>, Japan Post Bank <7182>, Seven & i Holdings <3382>, Toyota Motor <7203>, Sumitomo Mitsui FG <8316>, etc. declined, resulting in mixed overall performance. Chicago Nikkei 225 futures market.
Keros Therapeutics' Licensing Deal With Takeda Aligns With Broader Opportunity For Elritercept: Analyst
Keros Therapeutics Enters Global Development, License Deal With Takeda Pharmaceutical for Elritercept